

Presentation of the proposed Board

The Nomination Committee's proposal for the Board of Directors of BioArctic AB prior to the Annual General Meeting 2026

NEW ELECTION

Linda Nilsson (1979)

Proposed as director:

2026

Holdings in BioArctic:

Linda Nilsson is a board member and minority owner in the Gellerfors family's holding company Ackelsta AB. Ackelsta AB owns 5,759,998 A-shares and 12,143,201 B-shares.

Education:

Master of Science in Business and Economics from the Stockholm School of Economics.

Other current assignments:

-

Linda Nilsson has over 20 years of global experience from the international fashion company H&M. She currently holds the position as Head of Product Operations & Development, where she leads approximately 400 employees and is responsible for strategy, governance, and delivery across both product and production. Previously, Linda was Global Managing Director for Womenswear, with full P&L responsibility for a business area generating 40 billion SEK in revenue. She has extensive experience in strategic and transformational work, as well as in driving operational efficiency, always with a strong commercial and financial focus.

Linda Nilsson is independent in relation to the company and its management, but not to its major shareholders.

Philip Scheltens (1957)

Proposed as director:

2026

Holdings in BioArctic:

Philip Scheltens does not own any shares in BioArctic directly or indirectly. However, Philip Scheltens is a partner at EQT and is responsible for EQT's dementia fund LSP Dementia Fund. LSP Dementia Fund owns 347,500 B-shares.

Education:

MD (neurology) and holds a PhD in Medicine from the VU University Amsterdam and is Professor Emeritus of Neurology at the Amsterdam University Medical Center.

Other current assignments:

Partner and Head of the Dementia Fund in the EQT Life Sciences team.

Philip Scheltens is one of the leading international experts in the research, diagnosis and treatment of Alzheimer's disease. Prof. dr. Philip Scheltens studied at the VU University Amsterdam, Netherlands, gaining his MD in 1984, and PhD in 1993. He was appointed as Professor of Cognitive Neurology in 2000 and founded the Alzheimer Center at Amsterdam University Medical Centers in that same year, which he directed until 2022. Currently he is partner at EQT group and heads the Dementia Fund at EQT Life Sciences, that he started in 2020. He has been the (inter)national Principal Investigator (PI) for over 35 studies, including phase 1-3 multicenter clinical trials and supervised >100 PhD theses since 2000. He (co) authored over 1,250 peer reviewed articles to date. He founded and led the Dutch National Plan against dementia and served as chair of the board until 2021 and was on the advisory panel of the Dutch National Strategy for Dementia until 2025. He acted as chair of the World Dementia council from 2021 – 2025 and is medical advisor to the Race Against Dementia charity and member of the scientific advisory board of the Dementia research Institute.

Philip Scheltens is independent in relation to the company and its management, and to its major shareholders.

RE-ELECTION

Eugen Steiner (1954)

Proposed chairman of the Board

Chairman since:	2023
Director since:	2017
Holdings in BioArctic:	89,000 B-shares
Education:	Karolinska Institutet (Sweden) (licensed physician, Doctor of Clinical Pharmacology).
Other current assignments:	Chairman of the board of Empros Pharma AB. Board member of Inbox Capital AB and Stockholm School of Entrepreneurship. Member of Royal Swedish Academy of Engineering (IVA) and chairman of its Division X, Biotechnology.

Eugen Steiner is independent in relation to the company, its executive management and the major shareholders of the company.

Cecilia Edström (1966)

Director since:	2023
Holdings in BioArctic:	6,500 B-shares
Education:	Bachelor of Science in Finance and Economics from the Stockholm School of Economics
Other current assignments:	Founder and CEO, ceed konsult AB. Board member of Flerie AB and A3P Biomedical AB. Advisory Board Member, European Patient Safety Foundation (EUPSF). Chairman of the board of Perspetivo AB.

Cecilia Edström is independent in relation to the company, its executive management and the major shareholders of the company.

Anna-Lena Engwall (1971)

Director since:	2024
Holdings in BioArctic:	792 B-shares
Education:	Bachelor of Science in Nursing, Karolinska Institute, Stockholm. Diploma DIHM Marketing & Management, IHM Business School, Stockholm.
Other current assignments:	Global Commercial Vice President Cardiovascular at AstraZeneca, based in Cambridge, UK.

Anna-Lena Engwall is independent in relation to the company, its executive management and the major shareholders of the company.

Lars Lannfelt (1949)

Director since:	2003
Holdings in BioArctic:	8,639,998 A-shares and 19,685,052 B-shares through Demban AB, 7,000 B-shares privately.
Education:	Medical degree (specialist in psychiatry) and doctoral thesis at Karolinska Institutet, Stockholm, Sweden; Associate Professor of Neurogenetics at Karolinska Institutet, specialist in geriatrics.

Other current assignments: Board member of Demban AB.

Lars Lannfelt controls 31.8 percent of the share capital and 48.5 percent of the votes in the company and is employed in the company. Lars Lannfelt is thereby not independent in relation to the company, its executive management nor the major shareholders of the company.

Lotta Ljungqvist (1961)

Director since: 2021
Holdings in BioArctic: 3,159 B-shares
Education: Degree in biochemistry from KTH Royal Institute of Technology in Stockholm, Sweden. Doctorate in biochemical technology.

Other current assignments: Board member of Atlas Antibodies AB, Genovis AB, NorthXBiologics AB and BioLamina AB.

Lotta Ljungqvist is independent in relation to the company, its executive management and the major shareholders of the company.

Mikael Smedeby (1968)

Director since: 2018
Holdings in BioArctic: 4,422 B-shares
Education: Master of Laws, Uppsala University, Sweden. Military Reserve Officer training at InfoOHS and InfSS.

Other current assignments: Lawyer and partner at Advokatfirman Lindahl. Chairman of the board of Sallénggruppen AB (including subsidiaries) and Uppsala Akademiförvaltning. Board member of Coeli Group AB (publ) (including certain subsidiaries), in Sirius Fotboll and Mikael Smedeby Advokat AB.

Mikael Smedeby is independent in relation to the company, its executive management and the major shareholders of the company.

The information regarding board assignments and holdings of shares is as of 31 March 2026 and also includes any changes thereafter known to the company.